LFA-1 antagonist compounds
US6872735B2 · kind B2 · utility
29Cited by
1References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 11, 2003 |
| Grant date | Mar 29, 2005 |
| Priority date | — |
| Expiry date | Jul 11, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to novel compounds having formula (I) wherein Cy, X, Y, L and R1-6 are as defined herein. The compounds bind CD11/CD18 adhesion receptors such as Lymphocyte Function-associated Antigen-1 (LFA-1) and are therefore useful for treating disorders mediated by LFA-1 such as inflammation and autoimmune diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.